- 1 Risk factors for mortality of adult inpatients with Coronavirus disease 2019 (COVID-19): a
- 2 systematic review and meta-analysis of retrospective studies
- 4 Mohammad Parohan^a*, PhD, Sajad Yaghoubi^b*, PhD, Asal Seraj^c, PhD, Mohammad Hassan
- 5 Javanbakht^a, PhD, Payam Sarraf^d, MD, Mahmoud Djalali^{a*}, PhD
- 7 aDepartment of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics,
- 8 Tehran University of Medical Sciences, Tehran, Iran.
- 9 bDepartment of Clinical Microbiology, Iranshahr University of Medical Sciences, Iranshahr,
- 10 Iran.

20

3

6

- ^cDepartment of Nursing, Damavand Branch, Islamic Azad University, Damavand, Iran.
- dIranian center of Neurological research, Neuroscience Institute, Tehran University of Medical
- 13 Sciences, Tehran, Iran.
- *Corresponding author:
- 16 Mohammad Parohan
- 17 Postal address: Tehran University of Medical Sciences, School of Nutritional Sciences and
- 18 Dietetics .44 Hojat Dost St, Naderi St, Enghelab Ave, Tehran, Iran. E-mail address:
- 19 prohan.m742@gmail.com, prohan-m@razi.tums.ac.ir
- 21 *Additional corresponding authors
- 22 Mahmoud Djalali, Email address: mjalali87@yahoo.com
- 23 Sajad Yaghoubi, Email address: sajadyaghoubi98@gmail.com

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Abstract Background: Coronavirus disease 2019 (COVID-19) is an emerging disease that was first reported in Wuhan city, the capital of Hubei province in China, and has subsequently spread worldwide. Risk factors for mortality have not been well summarized. Current meta-analysis of retrospective cohort studies was done to summarize available findings on the association between age, gender, comorbidities and risk of death from COVID-19 infection. Methods: Online databases including Web of Science, PubMed, Scopus and Google scholar were searched to detect relevant publications up to 22 March 2020, using relevant keywords. To pool data, random-effects model was used. Furthermore, sensitivity analysis and publication bias test were also done. Results: In total, six retrospective studies with 22,350 COVID-19 infected patients and 741 cases of death were included in the current meta-analysis. A significant positive association was found between older age (≥65 years old) and COVID-19 mortality (combined effect size=2.39 (over twofold), 95% CIs=1.75-3.28, p<0.001). Such finding was also seen for hypertension (combined effect size=3.29 (over threefold), 95% CIs=1.54-7.05, p=0.002), diabetes (combined effect size=3.11 (over threefold), 95% CIs=1.10-8.80, p=0.032), chronic obstructive pulmonary disease (COPD) (combined effect size=7.69 (over sevenfold), 95% CIs=5.65-10.47, p<0.001) and cardiovascular diseases (CVDs) (combined effect size=7.39 (over sevenfold), 95% CIs=2.88-18.96, p<0.001). Conclusions: Older age, hypertension, diabetes, COPD and CVDs were associated with greater risk of death from COVID-19 infection. These findings could help clinicians to identify patients with poor prognosis at an early stage.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Keywords: COVID-19; novel coronavirus; SARS-CoV-2; Mortality; Meta-analysis. Introduction In December, 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously known as 2019-nCoV) was first reported in Wuhan city, the capital of Hubei province in China, and has subsequently spread to other regions of China and 199 countries and territories (1-3). SARS-CoV-2, which belongs to a unique clade of the sarbecovirus subgenus of the Orthocoronavirinae subfamily (4), was later designated coronavirus disease 2019 (COVID-19) in February, 2020, by World Health Organization. Patients with COVID-19 present primarily with fever, dry cough and fatigue or myalgia (5). Although most patients with COVID-19 are thought to have a favorable prognosis, older patients and those with chronic diseases may have worse outcomes (6). Patients with chronic underlying conditions may develop viral pneumonia, dyspnea and hypoxemia within 1week after onset of the disease, which may progress to respiratory or end-organ failure and even death (7). Several studies have reported the clinical characteristics and risk factors associated with death in patients with COVID-19 pneumonia (2, 6, 8-11). We are aware of no systematic review and metaanalysis that summarized available findings in this regard. Thus, we aimed to systematically review the present evidences on the association between age, gender, hypertension, diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular diseases (CVDs) and risk of death from COVID-19 infection, and to summarize the available findings in a meta-analysis.

67 Materials and methods 68 Study protocol 69 The present systematic review and meta-analysis were planned, conducted and reported in 70 adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 71 guidelines (12). 72 Search strategy 73 We performed a literature search using the online databases of ISI Web of Science, PubMed, 74 Scopus and Google scholar for relevant publications up to 22 March 2020. The following medical 75 76 subject headings (MeSH) and non-MeSH keywords were used in our search strategy: ("novel coronavirus" OR "SARS-CoV-2" OR "COVID-19") AND ("death" OR "mortality" OR "survival" 77 78 OR "fatal outcome"). Literature search was done by two independent researchers (MP and SY). 79 We also searched the reference lists of the relevant articles to identify missed studies. No restriction 80 was applied on language and time of publication. To facilitate the screening process of articles 81 from databases, all literature searches were downloaded into an EndNote library (version X8, 82 Thomson Reuters, Philadelphia, USA). 83 84 Eligibility Criteria In our meta-analysis, eligible articles were included if they met the following inclusion criteria: 85 86 (1) all studies assessing the association between age, gender, comorbidities and mortality risk from COVID-19 infection as the major outcomes of interest; (2) observational studies with retrospective 87

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

design; (3) those that reported hazard ratios (HRs), odds ratios (ORs) or relative risks (RRs) along with 95% confidence intervals (CIs) for the relationship between risk factors and COVID-19 mortality. Review articles, expert opinion articles, theses and books were excluded. Data extraction and assessment for study quality Two investigators (MP and AS) extracted the following data from the included studies: study design, the first author's name, the publication year, age and gender of patients, sample size, exposure (risk factors), outcome (the risk of mortality), exposure and outcome assessment methods, most adjusted risk estimate (HRs, ORs, RRs) with 95% confidence intervals and adjusted confounding variables. The Newcastle–Ottawa Scale (NOS) was used for assessing the quality of included retrospective cohort studies based on the following three major components: selection of the study patients, adjustment for potential confounding variables and assessment of outcome (13). Based on this scale, a maximum of nine points can be awarded to each study. In the present study, articles with the NOS score of ≥ 5 were considered as high quality publications. Statistical analysis We used HRs, ORs, and RRs (and their 95% confidence intervals) reported for the association between risk factors and mortality from COVID-19 infection, to calculate log RRs and their standard errors (SEs). Then, the overall effect size for mortality in relation to risk factors was calculated using random-effects model. For examining the between-study heterogeneity, we

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

performed the Cochran's O test ($I^2 > 50\%$ were considered between-study heterogeneity) (14). To identify potential sources of heterogeneity, we did subgroup analysis according to the predefined criteria as follows: age (≥65 vs. <65), gender (male vs. female), hypertension (yes vs. no), diabetes (yes vs. no), COPD (yes vs. no) and CVDs (yes vs. no). In addition to the main analysis, we carried out sensitivity analysis to find if the overall estimate depended on the effect size from a single study. Assessing the publication bias was done by the formal test of Egger (15). All statistical analyses were conducted using Stata, version 14.0 (Stata Corp, College Station, TX, USA). Pvalues were considered significant at level of < 0.05. Results Search results In our initial search, we found 135 papers. Of these, 15 duplicates, 17 non-English, 26 non-human, 46 reviews and 17 studies that did not fulfill our eligibility criteria were excluded, leaving 14 papers for further evaluation. Out of remaining 14 papers, 8 were excluded because of the following reason: did not report HRs, ORs or RRs with 95% CIs. Finally, we included 6 retrospective studies in the current systematic review and meta-analysis (Figure 1). Study characteristics All studies were conducted in Wuhan, China and used retrospective cohort design (2, 6, 8-11). The sample size of studies varied from 172 to 20812 patients (mean age, 58.7 years). Five studies used

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

real-time reverse transcriptase–polymerase chain reaction (RT-PCR) (2, 6, 8, 10, 11) and one study used clinical features (9) to identify COVID-19 infection. The NOS scores ranged between 5 to 8. Demographic characteristics and risk of death from COVID-19 In the meta-analysis of six effect sizes, obtained from six studies (2, 6, 8-11) (22,350 patients and 741 cases of death), we found that older age (\geq 65 years old) was associated with a 239% (over twofold) increased risk of COVID-19 mortality (combined effect size=2.39, 95% CIs=1.75-3.28, p<0.001, I²=95.4%, p_{heterogeneity}<0.001) (Figure 2). Combining five effect sizes from five studies (2, 6, 8-10) revealed no significant association between gender (male vs. female) and COVID-19 mortality (combined effect size=1.25, 95% CIs=0.75-2.09, p=0.399, I²=83.8%, p_{heterogeneity}<0.001) (Figure 2). Comorbidities and risk of death from COVID-19 Totally, fifteen effect sizes from five studies (2, 6, 8, 10, 11) with a total of 21,640 patients and 652 cases of death were extracted for the association between comorbidities and COVID-19 mortality. Combining the reported estimates, we found a significant positive association between (combined effect size=3.29, 95% CIs=1.54-7.05, p=0.002, I^2 =86.3%, hypertension pheterogeneity < 0.001), diabetes (combined effect size=3.11, 95% CIs=1.10-8.80, p=0.032, I²=91.3%, pheterogeneity < 0.001), COPD (combined effect size=7.69, 95% CIs=5.65-10.47, p<0.001, I²=0.0%, pheterogeneity=0.919), CVDs (combined effect size=7.39, 95% CIs=2.88-18.96, p<0.001, I²=61.5%, pheterogeneity=0.075) and risk of death from COVID-19 (Figure 3). We found that hypertension, diabetes, COPD and CVDs were associated with 329% (over threefold), 311% (over threefold),

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

769% (over sevenfold) and 739% (over sevenfold) higher risk of COVID-19 mortality, respectively. Sensitivity analysis and publication bias Findings from sensitivity analysis showed that overall estimates on the association of demographic characteristics and comorbidities with COVID-19 mortality did not depend on a single study. Furthermore, based on the results of Egger's test (hypertension; P=0.077, diabetes; P= 0.65, COPD; P=0.456 and CVDs; P=0.401), we found no evidence of publication bias. Discussion Findings from the current systematic review and meta-analysis supported the hypothesis that older age (≥65 years old), hypertension, diabetes, COPD and CVDs were associated with higher risk of mortality from COVID-19 infection. To the best of our knowledge, current study is the first metaanalysis to summarize earlier retrospective studies on the association between demographic characteristics, comorbidities and risk of death from COVID-19. Our findings are partially in agreement with previous narrative review (16). Previously, older age has been reported as an important risk factor for mortality in SARS and Middle East respiratory syndrome (MERS) (17, 18). The current meta-analysis confirmed that increased age (≥65 years old) was associated with death in COVID-19 patients. The age-dependent defects in B-cell and Tcell function and the excess production of type 2 cytokines could lead to prolonged proinflammatory responses and deficiency in control of viral replication, potentially leading to

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

poor outcome (19). In addition, elderly patients may have other risk factors, such as sarcopenia and comorbidities (11). Previous studies suggested that COVID-19 infection is more likely to affect older males with comorbidities, and can result in fatal respiratory diseases such as acute respiratory disease syndrome (10, 20). Interestingly, SARS and MERS also infected more males compared to females (21, 22). Differences in the levels and type of circulating sex hormones in males and females might influence the susceptibility of COVID-19 infection. Previous study showed that sex hormones modulate the responses of adaptive and innate immunity (23). However, our findings showed that gender was not a risk factor for mortality in COVID-19 patients. The other risk factors related to death include hypertension, diabetes, respiratory system disease and CVDs. A previous study showed that hypertension and diabetes are more prevalent in patients with severe MERS infection (22). Similarly, the mortality rate of influenza was significantly higher in patients with hypertension, metabolic disease, CVDs and respiratory system disease (24). Previous studies reported that high protein expression of angiotensin converting enzyme 2 (ACE2) receptor, the receptor for COVID-19, in specific organs correlated with organ failures in SARS patients (25-28). It has been shown that circulating ACE2 levels are higher in patients with hypertension, diabetes and CVDs (29, 30). Therefore, patients with these comorbidities may be more prone to die from COVID-19 infection because of the high expression of ACE2 receptor, though further research on the mechanism is needed. The pathogenesis of COVID-19 is still not completely understood. Cytokine storm is thought to play an important role in disease severity (31). Neutrophilia was found in both the lung and peripheral blood of patients with SARS (32, 33). The severity of lung damage correlated with higher numbers of neutrophils and macrophages in the peripheral blood and extensive pulmonary

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

infiltration of these cells in patients with MERS (34-36). Neutrophils are the main source of cytokines and chemokines. The generation of cytokine storm can lead to acute respiratory distress syndrome, which is a leading cause of death in patients with SARS and MERS (36, 37). This may explain the positive association between high fever and acute respiratory distress syndrome found at the early stages of COVID-19 infection (6). The present study has some limitations. First, interpretation of our meta-analysis findings might be limited by the small sample size. However, by including studies conducted in different designated hospitals for COVID-19, we believe our findings are representative of cases in Wuhan, China. Second, our meta-analysis did not include data such as smoking history and body mass index, which are potential risk factors for disease severity and mortality. Conclusion Older age, hypertension, diabetes, COPD and CVDs were associated with greater risk of death from COVID-19 infection. The results of the present meta-analysis could help clinicians to identify high risk groups that should receive off-label medications or invasive supportive care, as soon as possible. Contributors: MP, SY, AS and MHJ conceived the study conception and design. MP, SY and PS contributed to the literature search. MP, SY, AS and MD performed the acquisition of data. MP, SY, MHJ and MD conducted the analysis and interpretation of data. MP, AS, PS and MD drafted the manuscript. MP, MHJ and MD contributed to critical revision of the manuscript.

Declaration of Competing Interest: None declared. Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Referrences:

- 243 1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for
- 244 global health governance. Jama. 2020;323(8):709-10.
- 245 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult
- inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020
- 247 Mar 11. PubMed PMID: 32171076. Epub 2020/03/15. eng.
- 3. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report-68. March
- 249 28, 2020.

242

- 250 4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
- 251 Pneumonia in China, 2019. The New England journal of medicine. 2020 Feb 20;382(8):727-33. PubMed
- 252 PMID: 31978945. Epub 2020/01/25. eng.
- 5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019
- novel coronavirus in Wuhan, China. Lancet (London, England). 2020 Feb 15;395(10223):497-506.
- 255 PubMed PMID: 31986264. Epub 2020/01/28. eng.
- 256 6. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory
- 257 Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
- JAMA internal medicine. 2020 Mar 13. PubMed PMID: 32167524. Pubmed Central PMCID: PMC7070509.
- 259 Epub 2020/03/14. eng.
- 260 7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics
- of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London,
- 262 England). 2020 Feb 15;395(10223):507-13. PubMed PMID: 32007143. Epub 2020/02/03. eng.
- 263 8. Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID-19 mortality-preliminary
- results. medRxiv. 2020.
- 265 9. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney impairment is associated with
- in-hospital death of COVID-19 patients. medRxiv. 2020.
- 267 10. Su VYF, Yang Y-H, Yang K-Y, Chou K-T, Su W-J, Chen Y-M, et al. The Risk of Death in 2019 Novel
- 268 Coronavirus Disease (COVID-19) in Hubei Province. Available at SSRN 3539655. 2020.
- 269 11. Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and Laboratory Predictors of In-
- Hospital Mortality in 305 Patients with COVID-19: A Cohort Study in Wuhan, China. China (2/24/2020).
- 271 2020.
- 272 12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and
- meta-analyses: the PRISMA statement. Annals of internal medicine. 2009;151(4):264-9.
- 274 13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of
- 275 nonrandomized studies in meta-analyses. European journal of epidemiology. 2010 Sep;25(9):603-5.
- 276 PubMed PMID: 20652370. Epub 2010/07/24. eng.
- 277 14. Higgins J, Wells G. Cochrane handbook for systematic reviews of interventions. 2011.
- 278 15. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical
- 279 test. Bmj. 1997;315(7109):629-34.
- 280 16. Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. Reviews in
- 281 medical virology. 2020 Mar 16:e2103. PubMed PMID: 32175637. Epub 2020/03/17. eng.
- 282 17. Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. Outcomes and prognostic factors in
- 283 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003 Nov
- 284 4;139(9):715-23. PubMed PMID: 14597455. Epub 2003/11/05. eng.
- 285 18. Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, et al. Predictors of mortality in Middle East
- 286 respiratory syndrome (MERS). Thorax. 2018 Mar;73(3):286-9. PubMed PMID: 28724637. Epub
- 287 2017/07/21. eng.

- 288 19. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clinical
- 289 infectious diseases: an official publication of the Infectious Diseases Society of America. 2005 Nov 15;41
- 290 Suppl 7:S504-12. PubMed PMID: 16237654. Epub 2005/10/21. eng.
- 29. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients
- infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. PubMed PMID: 32077115. Epub
- 293 2020/02/23. eng.
- 294 21. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based
- 295 Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. Journal of
- 296 immunology (Baltimore, Md : 1950). 2017 May 15;198(10):4046-53. PubMed PMID: 28373583. Pubmed
- 297 Central PMCID: PMC5450662. Epub 2017/04/05. eng.
- 298 22. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome
- 299 coronavirus (MERS-CoV): a systematic review and meta-analysis. International journal of infectious
- diseases: IJID: official publication of the International Society for Infectious Diseases. 2016 Aug;49:129-
- 301 33. PubMed PMID: 27352628. Epub 2016/06/30. eng.
- 302 23. Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. Clinical reviews in
- 303 allergy & immunology. 2019 Jun;56(3):308-21. PubMed PMID: 28963611. Epub 2017/10/01. eng.
- 304 24. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe
- or complicated influenza illness: systematic review and meta-analysis. Bmj. 2013 Aug 23;347:f5061.
- 306 PubMed PMID: 23974637. Pubmed Central PMCID: PMC3805492. Epub 2013/08/27. eng.
- 307 25. Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The novel
- 308 coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease
- 309 TMPRSS2 for entry into target cells. BioRxiv. 2020.
- 310 26. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are
- 311 independent predictors for mortality and morbidity in patients with SARS. Diabetic medicine: a journal
- of the British Diabetic Association. 2006 Jun;23(6):623-8. PubMed PMID: 16759303. Epub 2006/06/09.
- 313 eng.
- 314 27. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and
- causes acute diabetes. Acta diabetologica. 2010 Sep;47(3):193-9. PubMed PMID: 19333547. Epub
- 316 2009/04/01. eng.
- 317 28. Li R, Qiao S, Zhang G. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species
- 318 sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. The Journal of
- 319 infection. 2020 Apr;80(4):469-96. PubMed PMID: 32092392. Epub 2020/02/25. eng.
- 320 29. Patel SK, Velkoska E, Freeman M, Wai B, Lancefield TF, Burrell LM. From gene to protein-
- 321 experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Frontiers
- 322 in physiology, 2014;5:227. PubMed PMID: 25009501. Pubmed Central PMCID: PMC4067757. Epub
- 323 2014/07/11. eng.
- 324 30. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where does
- angiotensin-converting enzyme 2 fit in? Clinical and experimental pharmacology & physiology. 2013
- 326 Aug;40(8):551-9. PubMed PMID: 23432153. Epub 2013/02/26. eng.
- 327 31. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and
- 328 consequences of cytokine storm and immunopathology. Seminars in immunopathology. 2017
- 329 Jul;39(5):529-39. PubMed PMID: 28466096. Epub 2017/05/04. eng.
- 330 32. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute
- respiratory syndrome. Lancet (London, England). 2003 May 24;361(9371):1773-8. PubMed PMID:
- 332 12781536. Epub 2003/06/05. eng.
- 333 33. Wang YH, Lin AS, Chao TY, Lu SN, Liu JW, Chen SS, et al. A cluster of patients with severe acute
- respiratory syndrome in a chest ward in southern Taiwan. Intensive care medicine. 2004 Jun;30(6):1228-
- 335 31. PubMed PMID: 15105985. Epub 2004/04/24. eng.

Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, et al. Clinicopathologic, 34. Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. The American journal of pathology. 2016 Mar;186(3):652-8. PubMed PMID: 26857507. Epub 2016/02/10. eng. Min CK, Cheon S, Ha NY, Sohn KM, Kim Y, Aigerim A, et al. Comparative and kinetic analysis of 35. viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Scientific reports. 2016 May 5;6:25359. PubMed PMID: 27146253. Pubmed Central PMCID: PMC4857172. Epub 2016/05/06. eng. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. Journal of Korean medical science. 2016 Nov;31(11):1717-25. PubMed PMID: 27709848. Pubmed Central PMCID: PMC5056202. Epub 2016/10/07. eng. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in 37. critically ill patients with severe acute respiratory syndrome. Jama. 2003 Jul 16;290(3):374-80. PubMed PMID: 12865379. Epub 2003/07/17. eng.

 $Table\ 1.\ Characteristics\ of\ studies\ included\ in\ the\ meta-analysis.$

Authors (year)	Design of study	Country	Mean age (y)	Sample size	Sex	Death cases	COVID-19 ^a detection	Demographic and clinical characteristics	HR, OR or RR (95%CI) ^b	Adjustment
Wu et al.	Retrospective	China	51	201	F/M	44	real-time RT-	Age (≥65 vs <65 years)	HR: 6.17 (3.26-11.67)	-
(2020)	cohort						PCR	Gender (male vs female)	HR: 0.56 (0.30-1.05)	
								Hypertension (yes vs no)	HR: 1.70 (0.92-3.14)	
								Diabetes (yes vs no)	HR: 1.58 (0.80-3.13)	
Zhou et	Retrospective	China	56	191	F/M	54	real-time RT-	Age (≥65 vs <65 years)	OR: 1.10 (1.03-1.17)	study center
al. (2020)	cohort						PCR	Gender (male vs female)	OR: 0.61 (0.31-1.20)	•
								Hypertension (yes vs no)	OR: 3.05 (1.57-5.92)	
								Diabetes (yes vs no)	OR: 2.85 (1.35-6.05)	
								COPD (yes vs no)	OR: 5.40 (0.96-30.40)	
								CVDs (yes vs no)	OR: 2.14 (0.26-17.79)	
Caramelo	Retrospective	China	-	20812	F/M	504	real-time RT-	Age (≥65 vs <65 years)	OR: 18.82 (7.20-41.55)	age, gender and
et al.	cohort						PCR	Gender (male vs female)	OR: 1.85 (1.60-2.13)	comorbidities
(2020)								Hypertension (yes vs no)	OR: 7.42 (6.33-8.79)	
								Diabetes (yes vs no)	OR: 9.03 (7.39-11.35)	
								COPD (yes vs no)	OR: 7.79 (5.54-10.43)	
								CVDs (yes vs no)	OR: 12.83 (10.27-15.86)	
Cheng et	Consecutive	China	63	710	F/M	89	respiratory rate	Age (\geq 65 vs <65 years)	HR: 2.51 (1.64-3.86)	age, gender,
al. (2020)	cohort						$> 30/\min$, or	Gender (male vs female)	HR: 2.44 (1.53-3.87)	disease
							oxygen		(,	severity,
							saturation <			leukocyte count
							93%, or			and lymphocyte
							PaO2/FiO2 ratio			count
							≤ 300mmHg			
Su et al.	Retrospective	China	71.6	172	F/M	32	real-time RT-	Age (≥65 vs <65 years)	OR: 26.00 (7.50-89.8)	-
(2020)	cohort			=			PCR	Gender (male vs female)	OR: 1.53 (0.75–3.13)	
								Hypertension (yes vs no)	OR: 3.50 (1.10-10.80)	
								Diabetes (yes vs no)	OR: 1.90 (0.60-5.50)	
								COPD (yes vs no)	OR: 7.40 (0.80-67.00)	
								CVDs (yes vs no)	OR: 5.10 (1.70-15.60)	
Wang et	Retrospective	China	47.8	264	F/M	18	real-time RT-	Age (\geq 65 vs <65 years)	OR: 1.07 (1.01-1.13)	-
					-,		PCR	Hypertension (yes vs no)	OR: 2.24 (0.57-8.72)	

Abbreviations: ^aCOVID-19: Coronavirus diseases 2019, ^bHR: Hazard ratio, OR: Odds ratio, RR: Relative risk.




Figure 1. Flow chart of study selection.




Figure 2. Forest plot for the association between age, gender and risk of mortality from COVID-19 using random-effects model.




Figure 3. Forest plot for the association between comorbidities and risk of mortality from COVID-19 using random-effects model. Chronic obstructive pulmonary disease (COPD), Cardiovascular diseases (CVDs).